cytecare logo

Karnataka's First Hospital to Offer Life-saving CAR-T Cell Therapy

Learn More

Do you or your loved one have DLBCL?

If you have recently been diagnosed with diffuse large B-cell lymphoma (DLBCL), you may want to consider the ESCALADE study.


What is the ESCALADE study?

The ESCALADE study is a clinical research study designed to assess the effectiveness and safety of an investigational study drug in patients with diffuse large B-cell lymphoma (DLBCL). The investigational study drug is approved for patients with some other types of blood cancer, but is considered investigational in this study because it is not approved for patients with DLBCL like yours.

What is the investigational study drug?

Acalabrutinib is a BTK inhibitor. This drug can stop cancer cells from repairing themselves, causing the cancer cells to die. It may also prevent new cancer cells from growing.

Who can participate in the ESCALADE study?

You may be eligible to participate in the study, if you:

  • Are between 18 and 70 years old.
  • Have been diagnosed with Stage 2 to Stage 4 DLBCL.
  • Have not started to receive treatment for DLBCL.

There are other requirements that you will need to meet to join the study. A study doctor will go through these with you in more detail.

What will I be asked to do if I participate?

If you wish to participate in the study, you must first sign an Informed Consent Form, or ICF. The ICF explains the study and what you will need to do if you choose to take part. During the Informed Consent process, you should ask the study doctor and study team any questions, to ensure that you understand what will happen during the study.

You will then complete a screening process, during which the study team will carry out some assessments to see if you may begin the study treatment phase. During the screening process, if you met the enrolment criteria for the study, you will receive standard of care treatment, while you are being assessed to see if you meet the randomisation criteria and can continue in the study.

Study Treatment Phase (up to 6 months)

If you are able to continue with the study, you will be randomly assigned to receive one of the following:

  • Arm A-Acalabrutinib tablets (twice a day) in combination with standard of care chemotherapy treatment; or
  • Arm B-Placebo tablets (twice a day) in combination with standard of care chemotherapy treatment.

You will have an equal chance (50/50) of being assigned either of these options.

The study treatment phase can last up to 6 months. You will need to visit the study clinic periodically, until you or the study doctor decide you should stop receiving the study treatment.

Follow-up Phase

If your disease has not progressed after you have finished the treatment phase, you will enter the follow-up phase and:

  • Attend visits every 4 months for the first 3 years.
  • Attend visits every 6 months for the next 2 years.

If your disease has progressed after the treatment phase, instead of attending clinic visits you will be contacted by phone about every 6 months.


About Clinical Studies

Future development is needed in treating DLBCL. More treatment options are needed, and they need to be more effective for more patients.

Clinical research studies are an essential part of developing new treatment options for people living with all sorts of diseases and conditions. These studies provide valuable information about safety and effectiveness before a new drug or treatment is approved.

Clinical studies follow standard and are closely regulated. Strict safety measures protect study patients, and a written plan called a protocol ensures that study procedure is conducted in accordance with all standards and regulations.

Cytecare Hospitals is a participating center in a clinical trial for patients diagnosed with advanced stage Multiple Myeloma
(Generally considered to be disease related to bone marrow)

Patients who have been informed by their physician about their advanced stage of Multiple Myeloma and wish to participate in a research clinical trial of an advanced treatment can approach Cytecare Hospitals to participate in the ongoing study.

For booking an appointment
You can contact the Research Coordinator, Phone number: +91 - 8022176767
Email us at :
For more details about the study, click here
Know More

What happens next?

To learn more or to see if you or a loved one may qualify for the study